Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The glutamate receptor ionotropic kainate subtype (KARs) is a family of tetrameric ligand-gated cation channels activated by glutamate and kainic acid. These receptors mediate fast excitatory synaptic transmission in the CNS and modulate neurotransmitter release. They are composed of various combinations of five subunits: GluK1–GluK5. KARs are promising targets for pharmacotherapy in neurological diseases involving basal ganglia dysfunctions such as epilepsy or movement disorders.
Ligand-gated cation channel activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate Receptor Ionotropic Kainate Subtype (KAR).